-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24

Benzinga·12/17/2025 17:38:59
Listen to the news
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.